REG - Oxford Biomedica PLC - Oxford Biomedica Appoints Frank Mathias as CEO

Oxford BioMedicaAnnouncement

22/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221122:nRSV1343Ha&default-theme=true

RNS Number : 1343H  Oxford Biomedica PLC  22 November 2022

 

The information contained within this announcement is deemed by the Group to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 (as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018). Upon the publication of this announcement via
the Regulatory Information Service, this inside information is now considered
to be in the public domain.

 

Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

Oxford, UK - 22 November 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, today
announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO)
and Board Director, effective March 2023.

 

Dr Mathias brings world-class innovation and contract development and
manufacturing experience to Oxford Biomedica. Since 2016 he has served as CEO
of Rentschler Biopharma SE ("Rentschler"), which he has successfully developed
into a leading global, full-service CDMO. During the past six years, Dr
Mathias has overseen a tripling of revenues, transformed the business,
increased efficiencies and enhanced profitability even faster than revenues.
At Rentschler, he also led the acquisition and rapid integration of a new site
from Shire in Milford near Boston, US, and the establishment of a new gene
therapies unit in Stevenage, UK. During his tenure, Rentschler was also the
first CDMO in Europe to support the commercial production of the mRNA vaccine
for BioNTech and also successfully transferred the commercial production
process for Curevac's mRNA vaccine.

 

Prior to Rentschler, Dr Mathias was CEO of publicly listed Medigene AG, an
immuno-oncology company focusing on the development of T-cell-based cancer
therapies. Over the course of his 30-year career, Dr Mathias has also served
in senior roles at leading global pharmaceutical companies including Amgen,
Servier and Hoechst AG. In 2019 he was awarded the title of "EY Entrepreneur
of the Year" in Germany.

 

Dr Roch Doliveux will remain as Interim CEO of Oxford Biomedica until March
2023, at which point Dr Mathias will fully take over the role of CEO and Dr
Doliveux will resume the role of Non-Executive Chair.

 

Commenting on the appointment, Dr Roch Doliveux, Chair and Interim CEO of
Oxford Biomedica, said: "I, on behalf of the Board, am delighted to welcome
Frank as CEO of Oxford Biomedica. Frank is an outstanding patient centric
leader with impressive experience from a top-end CDMO as well as from
innovative biopharma companies. He has a strong track record of delivering
growth and driving performance and innovation which are core strengths
required to implement our strategy of becoming an innovative global viral
vector leader. I know that Frank will drive our viral vector leadership to
unleash the potential of cell and gene therapy for biopharma companies to save
many lives."

 

Dr Frank Mathias, incoming Chief Executive Officer, said: "Oxford Biomedica is
a world-leader in the innovative development and manufacture of viral vectors
for life-saving cell and gene therapies, demonstrated by the ever-expanding
customer base of now more than 20 programmes across all vector types. With
momentum continuing to build across the business, I am excited by the
potential for the Company. I look forward to joining Oxford Biomedica and
working with all of the staff, the Board and partners to execute the strategy
and deliver the next phase of growth as a world-class, innovation-led CDMO
helping to improve the lives of patients."

 

Relevant Disclosures

 

There are no disclosures required to be made in accordance with LR 9.6.13R.

 

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc:

 

Roch Doliveux, Chair and Interim CEO - T: +44 (0)1865 783 000

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 919 539 1234

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0)7394 562 425

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Cole            / Angela Gray

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
US based subsidiary AAV manufacturing and innovation business, based near
Boston, US.

 

Further information is available at www.oxb.com (http://www.oxb.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBBDBGSDDGDB